ACHV

Business Context and Reporting Period

Company: OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.)
Reporting Period: Fiscal year ended December 31, 2008
Business Overview: A clinical-stage biopharmaceutical company focused on developing cancer therapies that address treatment resistance. The company's pipeline includes five product candidates, with the lead candidate, OGX-011 (custirsen sodium), in Phase 2 trials for castrate-resistant prostate cancer (CRPC) and non-small cell lung cancer (NSCLC).
Corporate Action: On August 21, 2008, the company completed a reverse acquisition of OncoGenex Technologies Inc. (the "Arrangement"). For accounting purposes, OncoGenex Technologies is deemed the acquirer. The 2008 financial results reflect OncoGenex Technologies operations from January 1 to August 20, 2008, and the combined company from August 21, 2008, through year-end.

Key Financial Metrics

Note: The 2008 Net Loss includes a $4.4 million extraordinary gain resulting from negative goodwill recognized during the reverse acquisition. Excluding this gain, the operating loss was approximately $8.6 million.

Material Changes vs. Prior Period

• Reverse Acquisition Impact: The most significant change was the August 2008 Arrangement with OncoGenex Technologies. This transaction resulted in a $4.4 million extraordinary gain (negative goodwill) and a substantial increase in cash and marketable securities (from $5.1M to $12.4M) due to assets acquired from Sonus.
• Expense Fluctuations: Research and Development (R&D) expenses increased by $3.7 million to $7.8 million, driven by the development of OGX-427 and increased personnel/facility costs post-merger. General and Administrative (G&A) expenses decreased slightly by $0.2 million to $3.3 million.
• Balance Sheet Restructuring: Total liabilities decreased significantly due to the extinguishment of convertible debentures and preferred shares upon the completion of the Arrangement. Stockholders' equity turned positive ($10.7M) from a deficit of $(38.2M) in 2007, primarily due to the issuance of common stock in the transaction and the elimination of preferred share accretion.

Guidance, Outlook, and Risks

Outlook and Capital Needs: The company has no revenue and expects to continue incurring losses. Management believes current cash resources ($12.4 million) are sufficient to fund operations through February 2010. However, additional funding is required to initiate planned Phase 3 clinical trials for OGX-011. The company intends to seek funding through partnerships, licensing, or equity/debt offerings. There is no assurance that funding will be available on favorable terms.

Clinical Progress:

• OGX-011: Phase 2 results in CRPC showed a median survival advantage of 27.5 months (OGX-011 + docetaxel) vs. 16.9 months (docetaxel alone). The company is designing Phase 3 trials and has received FDA Fast Track designation.
• OGX-427: Phase 1 monotherapy evaluation is complete; combination trials with docetaxel are ongoing.
• SN2310: Phase 1 trial completed; dose-limiting toxicity (neutropenia) was identified.

Key Risks:

• Liquidity Risk: Dependence on external financing to continue operations and fund Phase 3 trials. Failure to secure funding could force a curtailment of development.
• Clinical Risk: No products are approved for sale. Phase 3 trials may fail to demonstrate efficacy or safety, preventing regulatory approval.
• Intellectual Property: Reliance on licensed technology from Isis Pharmaceuticals and the University of British Columbia (UBC). Patent expiration and potential infringement claims pose risks.
• Lease Obligations: The company has a non-cancellable lease for excess office space in Bothell, WA, with a liability of approximately $1.7 million recognized for the excess facility.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $12.4 million cash balance to fund operations through early 2010 and the specific capital requirements for the planned Phase 3 trials.
• OGX-011 Phase 3 Design: Confirm the status of discussions with the FDA regarding the design of the Phase 3 registration trials (survival vs. pain palliation endpoints).
• Lease Liability: Review the company's strategy and progress in subleasing or exiting the excess Bothell, WA facility to mitigate the $1.7 million restructuring liability.
• Partnership Status: Monitor announcements regarding potential collaboration or licensing agreements to fund the development of OGX-011.
• Escrow Shares: Note that all milestone shares held in escrow from the Arrangement were released by December 31, 2008, following positive Phase 2 data and FDA meetings.